Emergent BioSolutions (NYSE: EBS) reported Q1 EPS of ($0.03), $0.25 worse than the analyst estimate of $0.22. Revenue for the quarter came in at $117.8 million versus the consensus estimate of $140.42 million.

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.